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Insulin-Like Growth Factor-1 (IGF-1) Reduces
ischemic changes and increases circulating
angiogenic factors in experimentally - induced
myocardial infarction in rats
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Abstract
Background: Coronary artery disease is a global health concern in the present day with limited therapies.
Extensive efforts have been devoted to find molecular therapies to enhance perfusion and function of the
ischemic myocardium. Aim of the present study was to look into the effects of insulin like growth factor -1 (IGF-1)
on circulating angiogenic factors after myocardial ischemia in rats.
Methods: Adult male Sprague-Dawley rats were randomly divided into 10-days control, myocardial infarction, IGF-1
alone (2 μg/rat/day) and ISO+IGF-1 groups. Isoproterenol (ISO), a synthetic catecholamine was used to induce
myocardial infarction. Serum transforming growth factor-b (TGF-b) and vascular endothelial growth factor (VEGF)
levels were checked after 10-days of IGF-1 administration.
Results: There was a significant increase in heart weight after IGF-1 treatment. A significant increase in cardiac
enzyme level (CK-MB and LDH) was seen in isoproterenol treated rats when compared to control group. IGF-
1treatment induced a significant increase in serum angiogenic factors, IGF-1, VEGF and TGF beta levels. IGF-1 also
reduced the ischemic changes in the myocardium when compared to the isoproterenol alone treated group.
Conclusions: In conclusion, treatment with insulin-like growth factor-1 (IGF-1) in myocardial infarction significantly
increased circulating angiogenic growth factors like IGF-1, VEGF and TGF beta thus, protecting against myocardial
ischemia.
Background
Cardiovascular disease is the leading cause of mortality,
not only in the Western world, but also in developing
countries [1]. Coronary artery disease is a global health
concern today, with limited treatment options available
to address this disorder. Extensive efforts have been
devoted to molecular therapies to enhance perfusion
and function of the ischemic myocardium [2]. Angio-
genesis is a process involving the formation of new
blood vessels from the pre-existing vasculature that
occurs in many physiological and pathological situations
[3]. Although neovascularization is an important
vascular response to chronic hypoxia, the role of angio-
genesis in myocardial ischemia remains unclear [4,5].
Therapeutic angiogenesis is being tested as a novel
treatment for ischemic heart disease [2]. In this connec-
tion, the challenge in the last decennium has been to
find methods of inducing new vascular growth in the
ischemic myocardium of patients suffering from athero-
sclerotic coronary artery disease where treatment by bal-
loon angioplasty or coronary by-pass grafting is
inappropriate. Therapeutic angiogenesis with recombi-
nant vascular endothelial growth factor proteins or with
the genes encoding the proteins holds new promise for
the treatment of cardiovascular disease [6-9].
Ischemic changes are known to induce a significant
alteration in the levels of circulating angiogenic and
anti-angiogenic factors. Members of the family of
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vascular endothelial growth factors (VEGFs) are major
stimulators of the growth of new blood vessels. Among
the most potent growth factors that induce angiogenesis,
besides the VEGFs, are the fibroblast growth factors.
Together with vascular endothelial growth factors and
hepatic growth factors, they are known to have a revas-
cularization stimulating effect after ischemia [10,11].
Insulin-like growth factor-1 (IGF-1) is a peptide hor-
mone structurally related to insulin, and which has a
pleiotropic effect on cell growth and metabolism. IGF-1
is among several factors that have been suggested to
regulate predegenerative abnormalities [12]. The biologi-
cal actions attributed to IGF-1 include its chemo-attrac-
tant properties, ability to release cytokines, promotion of
angiogenesis and stimulation of extracellular matrix pro-
duction [13]. There are no reports on the effect of exo-
genous IGF-1 on angiogenesis in the ischemic heart. We
hypothesized that IGF-1 could play a protective role in
myocardial ischemia by enhancing the circulating levels
of angiogenic factors.
Myocardial injury induced by isoproterenol, a syn-
thetic catecholamine, is a standard experimental model
for the investigation of pharmacological protective
effects against ischemic injury [14]. The mechanism of
isoproterenol-induced myocardial injury includes cytoso-
lic calcium overload, lipid peroxide generation and pro-
coagulant activity [15,16]. The pathological process of
isoproterenol-induced myocardial damage is character-
ized by patchy areas of myocardial ischemia. This myo-
cardial injury has many similarities to the traditional
myocardial infarction attributed to ischemic coronary
disease [17].
The aim of the present research was to determine
whether a short term administration of IGF-1 had an
effect on circulating angiogenic factors following myo-
cardial ischemia in rats.
Methods
Animals
Adult male Sprague-Dawley rats (250-300 g) were accli-
matized over a week to standard laboratory conditions
(24 ± 3°C ambient temperature, 40-60% relative humid-
ity, and 12 h light-dark photoperiods) with food and
water ad libitum. Each rat was individually housed with
fresh bedding, food and water reservoir at the com-
mencement of the treatments. Protocols for the use of
animals and all the experimental procedures were
approved by the Institutional Research and Ethics
Committee.
Experimental treatments and assays
The rats were randomly assigned to the following
groups (six rats in each group): (a) Control (b) Isopro-
terenol-induced myocardial ischemia; (c) Insulin-like
growth factor-1 (IGF-1) alone and (d) Isoproterenol-
induced myocardial ischemia followed by treatment with
IGF-1. Isoproterenol (Sigma-Aldrich, USA; 85 mg/kg
body weight) was used to induce myocardial ischemia in
rats by subcutaneous injection for two consecutive days.
For treatments with IGF-1 (Sigma Aldrich, USA), 2 μg/
rat/day were subcutaneously administered daily for 10-
days. Control rats were injected with saline.
Twenty four hours after the last treatment, the rats
were anaesthetized with ether, and blood samples were
collected via cardiac puncture. The blood samples were
centrifuged at 6000 rpm at 4°C for 15 minutes to sepa-
rate out the serum that was stored at -80°C for bio-
chemical analysis.
The heart was dissected out, weighed, and a portion of
it was preserved in 10% formalin. Paraffin blocks were
prepared from the heart samples and thin sections (4
μM) were prepared and stained with haematoxylin-eosin
(H&E) for light microscopy. The sections were exam-
ined for necrosis, nuclear pyknosis, hypertrophy, angio-
genesis, scar formation and macrophage activity.
Commercially available enzyme-linked immunosorbant
assay (ELISA) kits were used for the quantitative deter-
mination of creatinine kinase-MB (CK-MB; BioCheck,
Inc., USA), insulin-like growth factor-1 (IGF-1; USCN
Life, China), vascular endothelial growth factor (VEGF;
USCN Life, China) and transforming growth factor-beta
(TGF-ß BioVendor, Czech Republic) concentrations in
rat serum.
Creatinine kinase - MB Assay
The assay system utilized a primary monoclonal anti-
body directed against an antigenic determinant on the
CK-MB. The antibody-enzyme conjugate consisted of
goat anti-CK-MB seconday antibody conjugated to
horseradish peroxidase (HRP). Colour development of
the TMB (3,3’5,5’ tetramethyl-benzidine) chromogenic
substrate was measured by absorbance at 450 nm.
Insulin-like Growth Factor (IGF-1) Assay
The micro titre plate provided in this kit was pre-coated
with a primary antibody specific to IGF-1. Standards or
samples are then added to the appropriate micro titre
plate wells together with a biotin-conjugated seconday
polyclonal antibody specific for IGF-1. Avidin conju-
gated to horseradish peroxidase (HRP) and a TMB
(3,3’5,5’ tetramethyl-benzidine) substrate completed the
immuno-reaction sequence that was ended with the
addition of a sulphuric acid solution. Colour change was
measured at 450 nm.
Transforming Growth Factor-b (TGF-b) Assay
In this assay, rat TGF-b present in samples bound to the
adsorbed primary anti-rat TGF-b antibodies in the
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micro titre wells. A HRP-conjugated secondary mono-
clonal anti-rat TGF-b antibody bound to rat TGF-b cap-
tured by the primary antibody. The reaction between
HRP and substrate solution was stopped by the addition
of an acidic solution and colour change was measured
at 450 nm.
Vascular Endothelial Growth Factor (VEGF) Assay
The micro titre plate provided in this kit was pre-coated
with the primary antibody. Standards or samples are
added to the appropriate micro titre plate wells together
with the seconday biotin-conjugated polyclonal antibody
preparation specific for VEGF. Avidin conjugated to
horseradish peroxidase (HRP) was added, followed by the
TMB (3,3’5,5’ tetramethyl-benzidine) chromogenic sub-
strate solution. The reaction was stopped by the addition
of acid and absorbance was measured at 450 nm.
Lactate dehydrogenase (LDH) activity was determined
using a commercial kit (LDH; BioAssay Systems, USA).
In this reaction, the enzyme substrate was oxidized with
the transfer of electrons to the tetrazolium salt MTT.
Absorbance of the reduced MTT was read at 565 nm
and LDH activity was calculated according to the equa-
tion provided in the kit.
Statistical Analysis
Global comparison among treatments was carried out
using the Kruskal Wallis non-parametric test, and pair-
wise comparisons between different groups were per-
formed using the Mann-Whitney-U test. The significance
of difference between treatments was set at p < 0.05.
Results
Histophathological examination showed robust myocar-
dium architecture and normal morphology in the control
group of rats. On the other hand, the isoproterenol
group displayed evidence of myocyte necrosis, neutrophi-
lic infiltration and areas of diffuse interstitial oedema,
suggestive of myocardial infarction. Rats treated with
insulin-like growth factor alone had normal myocardium
morphology with mild vascular proliferation whereas
those administered isoproterenol (ISO) showed evidence
of myocyte necrosis. This development was observed also
in rats treated with both isoproterenol (ISO) and IGF-1,
but to a lesser degree when compared with ISO treat-
ment alone. IGF-1 treatment induced capillary sprouting
in the necrotic areas, with more prominent macrophage
activity and scar formation, suggestive of healing. The
wound healing shows infilltration by inflammatory cells
and fibrosis, and most importantly there is a local angio-
genic reaction in the myocardium with many small ves-
sels in the surrounding area (Figure 1).
There was a significant (p < 0.05) decrease in mean
body weight of rats 10 days after ISO injection, but such
a change was not observed after IGF-1 administration to
the ISO-treated rats. IGF-1 alone increased the mean
body weight, but this was not statistically significant. An
increase in mean heart weight (p < 0.05) was recorded
after 10 days following IGF-1 treatment alone, as com-
pared with controls. Myocardial ischemia arising from
ISO treatment significantly increased (p < 0.05) heart
weight of rats when compared with corresponding mea-
surements in both the treated only with IGF-1 and con-
trol rats. IGF-1 applied to rats injected with ISO
attenuated the increase in heart weight due to ISO (p <
0.05; Table 1).
Compared with the untreated control rats, there were
significant increases (p < 0.05) in the cardiac enzymes,
CK-MB and LDH, 10 days after the induction of myo-
cardial ischemia by ISO treatment. However, these dif-
ferences were not observed between the control rats and
rats that were administered IGF-1 alone. Treatment
with IGF-1 in myocardial ischemia rats significantly
reduced (p < 0.05) CK-MB and LDH levels when com-
pared with untreated myocardial ischemia rats. Never-
theless, the levels of cardiac enzymes were still
significantly elevated in rats treated with ISO and IGF-1,
as compared with the control rats or rats injected with
IGF-1 alone (p < 0.05) (Table 2).
When serum IGF-1 levels were compared among the
different experimental groups, we observed that there
was a significant increase (p < 0.05), compared with
control, in IGF-1 level ten days after commencement of
the ISO treatment that led to myocardial ischemia.
Serum IGF-1 levels also showed a significant increase
Figure 1 Histopathological analysis of rat myocardium: A -
Normal appearance myocardial tissue in control rats. B - Normal
myocardium without any necrosis or nuclear pyknosis in IGF-1 alone
group, C - Myocardial infarction with ISO treatment (arrows)
showing necrosis and scar formation, D - Vascular proliferation and
macrophage activity in ISO + IGF-1 treated group. There is a local
angiogenic reaction in the myocardium with many small vessels in
the surrounding area (arrows), ×100.
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(p < 0.05) in rats following treatment with IGF-1 alone
and even more so in rats treated with both IGF-1 and
ISO (p < 0.05; Table 3).
Pair-wise comparisons showed that the angiogenic fac-
tors TGF-b and VEGF levels associated with the ISO
treatment alone, and ISO with IGF-1 treatment
increased significantly (p < 0.05) when compared with
the control level (Table 3).
Discussion
Our study showed that administration of isoproterenol
(ISO) (85 mg/kg) to rats for two consecutive days
resulted in severe myocardial injury, which was con-
firmed by elevations in heart weight and in levels of
serum CK-MB and LDH. This finding is in accordance
with previous studies that used ISO-induced myocardial
injury as an experimental model for the investigation of
pharmacological protective effects of several drugs
against ischemic injury [18]. The ISO treatment pro-
duced functional alterations to the myocytes, as mani-
fested by an increase in both the heart weight and serum
levels of the biomarkers for cardiac injury, CK-MB and
LDH. The biochemical results described in this study are
in consonance with earlier reports on ISO-induced myo-
cardial injury where increased cardiac biomarker levels
were observed [16]. Panda and Naik [19] in their research
study reported that there was a significant alteration in
biochemical parameters (increased levels of AST LDH
and CK-MB in serum) with the induction of myocardial
necrosis using ISO. Zhang et al. showed that a high-dose
of ISO produced relative hypoxia leading to ischemia by
excessive activation of b1-adrenergic receptors that in
turn resulted in increased inotropic, chronotropic and
dromotropic effects [20]. Another mechanism that might
operate is through the formation of reactive oxygen
species (ROS) arising from the auto-oxidation of ISO
leading to peroxidative damage [21].
In our study, we found that circulating levels of angio-
genic factors (TGF-b and VEGF) and the proangiogenic
growth factor IGF-1 were significantly increased after
ISO treatment. Ischemic injury is known to cause the
release of angiogenic factors such as cytokines and vas-
cular growth factors derived from the local tissue area
into the blood circulation (6, 7, 8). Our findings showed
that ischemic injury caused by ISO induced increased
secretion of the angiogenic factors. This could be an
adaptive response of the myocardium for repair and
revascularization to maintain oxygen supply after myo-
cardial hypoxia [22]. As reported by Folkman [23], phy-
siological response to the development of tissue
ischemia included the up-regulation of angiogenic
growth factors and mobilization of circulating cellular
elements that together enabled development of an
accessory vasculature. Rabinovsky et al. [13] opined that
angiogenesis occurred after ischemia when stimulated
by circulating angiogenic factors that helped in the regu-
lation of endothelial cell migration, cell survival and
endothelial cell proliferation [8,9,11,13].
There are numerous other known angiogenic factors
apart from the ones studied in this research that are
known to play an important role in revascularization
after ischemia in various tissues in the body. These
include angiogenin, angiopoietin-1, hepatocyte growth
factor and platelet derived growth factor [24]. There
have been no reports so far on the effect of circulating
angiogenic factors on myocardial infarction, except for
the role of VEGF on ischemic-induced changes in angio-
genesis that have been studied extensively. VEGF is
known to induce angiogenesis in the ischemic myocar-
dium by stimulating endothelial cell proliferation and
Table 1 Effect of insulin-like growth factor-1 on body weight and heart weight
Parameters Control IGF-1 M I M I + IGF-1
Body weight (g) 275.7 ± 4.18 282.18 ± 8.15 268.88 ± 2.17 * 270.44 ± 4.12
Heart weight
(g/100 g b.wt)
0.258 ± 0.017 0.287 ± 0.012* 0.321 ± 0.019 * ✞ 0.310 ± 0.014 * ✞ ■
Values are Mean ± SEM.
* Indicates significant difference when compared to control group (P < 0.05).
✞ Indicates significant difference when compared to IGF-1 group (P < 0.05).
■ Indicates significant difference when compared to M I group (P < 0.05).
Table 2 Effect of insulin-like growth factor-1 on cardiac biomarkers
Parameters Control IGF-1 M I M I + IGF-1
CK-MB (ng/mL) 3.319 ± 0.773 3.631 ± 0.669 5.662 ± 0.249 *✞ 4.262 ± 0.289 * ✞ ■
Lactate Dehydrogenase (IU/L) 24.574 ± 2.748 25.403 ± 2.664 80.040 ± 5.774 * ✞ 59.003 ± 2.688 *✞ ■
Values are Mean ± SEM.
* Indicates significant difference when compared to control group (P < 0.05).
✞ Indicates significant difference when compared to IGF-1 group (P < 0.05).
■ Indicates significant difference when compared to M I group (P < 0.05).
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migration [25]. Ma et al. found in their study that
TGF-b also played a role in angiogenesis by stimulating
extracellular matrix production, stabilizing newly formed
vessels and influencing the expression of other angio-
genic factors [26].
From our present study, significant increases in circu-
lating levels of VEGF and TGF-b were observed after
insulin-like growth factor-1 (IGF-) treatment at a dose
of 2 μg/rat/day in rats. Insulin-like growth factor is a
potent angiogenic agent [8,9,27-29] that promotes
angiogenesis in several physiological and pathological
conditions. Boucher et al. [30] showed that IGF-1 had
proangiogenic effects even at a dose as low as 1 μg/kg.
IGF-1 is postulated to induce angiogenesis through
interaction with locally produced factors such as VEGF
[28,31]. IGF-1 may increase the release of other
endothelial cell-derived angiogenic factors into the cir-
culation when this factor binds to its receptors on
endothelial cells [32]. Our findings confirmed that one
of the mechanisms by which IGF-1 promoted angiogen-
esis might be by stimulating the release of other angio-
genic factors such as VEGF and TGF-ß, which were
elevated in the serum of rats treated with IGF-1. These
responses in VEGF and TGF-ß levels were further ele-
vated in rats treated with both IGF-1 and ISO, the latter
inducing myocardial ischemia. Overall, histopathological
comparison of hearts from rats in ischemic group and
IGF-1treated groups showed that an obvious angiogenic
reaction occurred as a result of IGF treatment. Neovas-
cularization by such angiogenic agents may explain the
cardioprotective action of IGF during myocardial ische-
mia, the mechanism of which has yet to be fully eluci-
dated [33].
Another finding in the present study was that the
levels of both the biomarkers of cardiac injury, CK-MB
and LDH, were significantly attenuated after IGF-1
treatment of rats with induced myocardial ischemia.
These are positive findings suggesting that IGF-1 has a
beneficial cardioprotective role in ischemic heart disease.
Conclusions
IGF-1 treatment enhanced circulating levels of angio-
genic factors TGF-b and VEGF, while it reduced the
enzymes associated with cardiac injury (CK-MB and
LDH) in rats with induced myocardial infarction. IGF-1
treatment may be useful in enhancing regional myocar-
dial blood flow in the injured myocardium via the sti-
mulation of neovascularization attributable to the
increased presence of angiogenic factors. IGF-1 acts as a
critical permissive agent for the action of other angio-
genic growth factors in vascularisation in the myocar-
dium under ischemic conditions. Thus, IGF-1 has the
potential to be a novel and efficient therapeutic strategy
for myocardial infarction in humans for enhancing
angiogenesis.
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